Keytruda Closing In On First-Line Metastatic Triple-Negative Breast Cancer

But Has Ground To Make Up On Tecentriq

13 Feb 2020

• By John Davis

An interim analysis of the Phase III KEYNOTE-355 study in triple-negative breast cancer patients reports that first-line pembrolizumab combined with chemotherapy has met the PFS primary endpoint, but Merck & Co is still a long way behind Roche’s Tecentriq in the additional indication.

A closely watched clinical study involving Merck & Co. Inc.’s anti-PD-1 therapy Keytruda (pembrolizumab) has reported promising results at an interim analysis, in combination with chemotherapy as a first-line therapy for metastatic triple-negative breast cancer.

The pivotal Phase III KEYNOTE-355 study met one of its dual primary endpoints, improving progression-free survival in metastatic triple-negative breast...